Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Celon Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Celon Pharma kazanç ve gelirinin sırasıyla yıllık 116.1% ve 7.4% oranında artması tahmin edilirken, EPS'nin yıllık 105.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

116.1%

Kazanç büyüme oranı

105.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	15.5%
Gelir büyüme oranı	7.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	19 Sep 2024

Gelecekteki son büyüme güncellemeleri

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03

Kazanç ve Gelir Büyüme Tahminleri

WSE:CLN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (PLN Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	265	11	17	59	3
12/31/2025	293	25	8	62	4
12/31/2024	232	-5	-42	16	1
6/30/2024	207	-45	-12	6	N/A
3/31/2024	209	-34	-23	2	N/A
12/31/2023	214	-28	-41	-8	N/A
9/30/2023	214	-25	-31	7	N/A
6/30/2023	211	-30	-53	-16	N/A
3/31/2023	196	-47	-42	-8	N/A
12/31/2022	194	-39	-39	-5	N/A
9/30/2022	191	-31	-39	-10	N/A
6/30/2022	186	-28	-11	32	N/A
3/31/2022	191	-17	-17	25	N/A
12/31/2021	196	-12	3	44	N/A
9/30/2021	186	-11	7	60	N/A
6/30/2021	185	-2	3	57	N/A
3/31/2021	170	0	-18	71	N/A
12/31/2020	157	-1	-28	72	N/A
9/30/2020	142	4	-58	37	N/A
6/30/2020	128	5	-88	6	N/A
3/31/2020	109	3	-85	-19	N/A
12/31/2019	102	12	-70	-5	N/A
9/30/2019	110	17	-69	6	N/A
6/30/2019	118	23	-61	15	N/A
3/31/2019	124	29	-31	37	N/A
12/31/2018	125	30	-39	28	N/A
9/30/2018	116	30	-30	27	N/A
6/30/2018	109	26	-8	34	N/A
3/31/2018	107	28	N/A	26	N/A
12/31/2017	107	26	N/A	25	N/A
9/30/2017	129	22	N/A	18	N/A
6/30/2017	127	24	N/A	23	N/A
3/31/2017	115	27	N/A	28	N/A
12/31/2016	129	38	N/A	21	N/A
9/30/2016	111	42	N/A	34	N/A
12/31/2015	108	37	N/A	52	N/A
12/31/2014	98	52	N/A	24	N/A
12/31/2013	72	18	N/A	8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CLN önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.9% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: CLN önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: CLN önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: CLN şirketinin gelirinin (yıllık 7.4% ) Polish pazarından (yıllık 4.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CLN şirketinin gelirinin (yıllık 7.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CLN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Celon Pharma Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 26% to zł21.10

Consensus estimates of losses per share improve by 50%

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Price target decreased to zł27.55

Price target decreased to zł27.55

Price target decreased to zł29.32

Recent updates

Second quarter 2024 earnings released: zł0.15 loss per share (vs zł0.18 profit in 2Q 2023)

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

New minor risk - Shareholder dilution

Price target increased by 26% to zł21.10

Celon Pharma S.A. Announces Strong Proof-Of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Oral Antipsychotic

Now 67% overvalued after recent price rise

Upcoming dividend of zł0.08 per share

Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl’ 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)

Now 21% overvalued

Full year 2023 earnings released: zł0.55 loss per share (vs zł0.77 loss in FY 2022)

Consensus estimates of losses per share improve by 50%

Celon Pharma S.A. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Upcoming dividend of zł0.09 per share at 0.6% yield

Full year 2022 earnings released

Celon Pharma S.A. to Report Q3, 2023 Results on Nov 22, 2023

Third quarter 2022 earnings released

Price target decreased to zł27.55

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Price target decreased to zł27.55

Price target decreased to zł29.32

Second quarter 2022 earnings released

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Consensus EPS estimates fall by 27%

Upcoming dividend of zł0.29 per share

Price target decreased to zł32.32

Consensus forecasts updated

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Price target decreased to zł36.12

Consensus EPS estimates fall by 36%

Price target decreased to zł40.72

Price target decreased to zł43.23

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to zł45.23

Price target decreased to zł48.23

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Upcoming dividend of zł0.07 per share

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Price target increased to zł54.07

Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Price target raised to zł50.30

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma S.A. to Report Fiscal Year 2020 Results on Mar 31, 2021

Celon Pharma S.A. to Report Q1, 2021 Results on May 31, 2021

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Investor sentiment improved over the past week

New 90-day high: zł43.45

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Third quarter 2020 earnings released: EPS zł0.088

Market bids up stock over the past week

New 90-day low: zł38.25

First half earnings released

New 90-day high - zł44.25

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin